Connor, Clark & Lunn Investment Management (CC&L)
AMRX icon

Connor, Clark & Lunn Investment Management (CC&L)’s Amneal Pharmaceuticals AMRX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-623,258
Closed -$6.24M – 1526
2025
Q3 		$6.24M Buy
623,258
+20,790
+3% +$187K 0.02% 520
2025
Q2 		$4.87M Buy
602,468
+74,783
+14% +$564K 0.02% 581
2025
Q1 		$4.42M Sell
527,685
-27,970
-5% -$233K 0.02% 531
2024
Q4 		$4.4M Buy
555,655
+6,680
+1% +$56K 0.02% 515
2024
Q3 		$4.57M Sell
548,975
-9,138
-2% -$71.5K 0.02% 453
2024
Q2 		$3.54M Buy
558,113
+24,679
+5% +$157K 0.01% 512
2024
Q1 		$3.23M Buy
533,434
+56,528
+12% +$319K 0.01% 535
2023
Q4 		$2.89M Sell
476,906
-15,398
-3% -$68.6K 0.01% 577
2023
Q3 		$2.08M Buy
492,304
+107,090
+28% +$399K 0.01% 615
2023
Q2 		$1.19M Buy
385,214
+54,717
+17% +$117K 0.01% 745
2023
Q1 		$459K Buy
330,497
+96,380
+41% +$192K ﹤0.01% 911
2022
Q4 		$466K Buy
234,117
+80,427
+52% +$180K ﹤0.01% 877
2022
Q3 		$310K Buy
+153,690
New +$431K ﹤0.01% 915
2020
Q4 		– Sell
-18,014
Closed -$70K – 888
2020
Q3 		$70K Sell
18,014
-281,053
-94% -$1.2M ﹤0.01% 886
2020
Q2 		$1.42M Buy
299,067
+116,776
+64% +$481K 0.01% 530
2020
Q1 		$634K Buy
+182,291
New +$772K 0.01% 648

Other funds holding AMRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s AMRX Position: Q4 2025 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Amneal Pharmaceuticals (AMRX) in Q4 2025, closing a stake of 623,258 shares — an estimated $6.24M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in AMRX in Q1 2020 and held it in 16 quarters. The position peaked at $6.24M in Q3 2025. 277 funds tracked by Wall St. Rank hold AMRX as of Q4 2025.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Amneal Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 623,258 Amneal Pharmaceuticals shares in Q4 2025, an estimated $6.24M.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Amneal Pharmaceuticals in Q1 2020 and held it in 16 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Amneal Pharmaceuticals position peaked at $6.24M in Q3 2025.
  • 277 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q4 2025.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2025, filed 10 Feb 2026.